ArticleCureus2024
Isotretinoin and Suicide: Data Mining of the United States Food and Drug Administration Adverse Event Reporting System Database.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Divergent System Organ Class Safety Profiles of Isotretinoin Versus Topical Retinoids: An EudraVigilance Disproportionality Analysis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Real-World Evidence of Neuropsychiatric Adverse Reactions to Isotretinoin: Insights from EudraVigilance (2005-2025).Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Isotretinoin is a 13-cis-retinoic acid most commonly used to treat severe nodular acne. It may result in psychiatric adverse events, such as completed suicide, even though the exact mechanism is unknown. Despite extensive research, the potential link between isotretinoin and psychiatric side effects remains unclear. Objectives The main objective of this study is to find the relationship between isotretinoin and suicide-related adverse events by analyzing the United States Food and Drug Administration Adverse Event Reporting System (FAERS). Methods The study data were obtained from the FAERS database from 1982 to March 2024. The inclusion criteria were: (i) isotretinoin-related suicide and suicide-related adverse events; (ii) reports with specified age and gender. Out of the 73,076 extracted cases, 2839 were finalized for analysis based on the inclusion criteria. The data were represented as frequency and percentages. A chi-square or Fischer exact test was used to analyze the categorical variables. The P-value <0.05 was considered as statistically significant. Results As 2433 patients experienced multiple reactions, the reported suicide and suicide-related adverse events totalled 3,059. The most commonly affected individuals were males, with the exception of depression suicidal event, which was more common in females. Among all age groups, those aged 10-19 were the most affected, as the occurrence of acne and the use of isotretinoin were higher in this age group. Almost all the reactions were serious, and there were 349 completed suicides. Conclusion The usage of isotretinoin can increase the possibility of suicide-related adverse events and should be used cautiously, especially in adolescents and patients with previous psychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.